Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HUTCHMED (China) ( (HK:0013) ) has provided an update.
HUTCHMED has appointed Professor Tan Shao Weng, Daniel as an Independent Non-executive Director and a member of its Technical Committee. Professor Tan brings over 20 years of oncology experience, particularly in thoracic, head, and neck malignancies, and drug development. His expertise in targeted therapies and clinical oncology is expected to bolster HUTCHMED’s strategic growth and innovation in cancer drug development. This appointment reflects HUTCHMED’s ongoing commitment to enhancing its leadership team with experienced professionals to drive forward its mission in the biopharmaceutical industry.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought drug candidates from in-house discovery to patients worldwide, with its first three medicines marketed in China and one approved globally, including in the US, Europe, and Japan.
Learn more about 0013 stock on TipRanks’ Stock Analysis page.